Pheochromocytoma and paraganglioma (PPGL) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`None`

ID	`IND-SDHA-CARRIER-SYMPTOM-DRIVEN`
Type	Indication
Status	reviewed 2026-05-20 \| pending_clinical_signoff
Diseases	`DIS-PHEOCHROMOCYTOMA`
Sources	`SRC-ENDOCRINE-SOCIETY-MEN-2023` `SRC-NCCN-NET-2025`

Notes

STUB — v0.3 gene-specific PGL5 (SDHA) less-intensive symptom-driven alternative. Sibling — IND-SDHA-CARRIER-SURVEILLANCE (standard scheduled-imaging track). Engine binary framing labels this 'aggressive' but clinical intensity is LOWER than the standard track — labelling artefact, narrated in expected_outcomes.

Used By

Indication

IND-SDHA-CARRIER-SURVEILLANCE - IND-SDHA-CARRIER-SURVEILLANCE

Red flag

RF-SDHA-SPECIFIC-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in SDHA (succinate dehydrogenas...